Author:
Guner Yilmaz Bengisu,Akgun-Dogan Ozlem,Ozdemir Ozkan,Yuksel Bayram,Hatirnaz Ng Ozden,Bilguvar Kaya,Ay Beril,Ozkose Gulsah Sebnem,Aydin Eylul,Yigit Ayca,Bulut Aybike,Esen Fatma Nisa,Beken Serdar,Aktas Selma,Demirel Atalay,Arcagok Baran Cengiz,Kazanci Ebru,Bingol İbrahim,Umur Ozge,Sik Guntulu,Isik Ugur,Ersoy Melike,Korkmaz Ayse,Citak Agop,Mardinoglu Adil,Ozbek Ugur,Alanay Yasemin
Abstract
IntroductionRare and ultra-rare genetic conditions significantly contribute to infant morbidity and mortality, often presenting with atypical features and genetic heterogeneity that complicate management. Rapid genome sequencing (RGS) offers a timely and cost-effective approach to diagnosis, aiding in early clinical management and reducing unnecessary interventions. This pilot study represents the inaugural use of next-generation sequencing (NGS) as a diagnostic instrument for critically ill neonatal and pediatric ICU patients in a Turkish hospital setting.MethodsTen infants were enrolled based on predefined inclusion criteria, and trio RGS was performed. The mean age of the participants was 124 days, with congenital abnormalities being the most common indication for testing. Three patients had consanguineous parents. The mean turnaround time from enrollment to delivery of results was 169 h, with a diagnostic yield of 50%.ResultsThree patients received a definitive molecular diagnosis, impacting their clinical management. Two patients benefited from the exclusion of Mendelian conditions, leading to alternative diagnoses.DiscussionThis study demonstrates the feasibility and results of RGS in Turkish hospital settings, emphasizing the importance of timely genetic diagnosis in reducing the diagnostic odyssey for families and improving patient care. Further research is needed to evaluate the cost-effectiveness and applicability of RGS in the Turkish healthcare system for children with diseases of uncertain etiology.